The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.3M Compounds and 9.3K Targets. Of those, 1,372K data for 638K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

31 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.EBI
Goethe-University Frankfurt
New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships.EBI
Ono Pharmaceutical
Substituted (aryloxy)alkanoic acids as antagonists of slow-reacting substance of anaphylaxis.EBI
TBA
Synthesis and structure-activity relationship studies of a series of 5-aryl-4,6-dithianonanedioic acids and related compounds: a novel class of leukotriene antagonists.EBI
TBA
Development of new chromanol antagonists of leukotriene D4.EBI
Pfizer
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.EBI
Eli Lilly
Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists.EBI
Shanghai Institute of Materia Medica
Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.EBI
Glenmark Research Centre
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.EBI
Setsunan University
Discovery of a potent, orally available dual CysLT1 and CysLT2 antagonist with dicarboxylic acid.EBI
Ono Pharmaceutical
Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.EBI
Ono Pharmaceutical
Leukotriene receptor antagonists. 2. The [[(tetrazol-5-ylaryl)oxy]methyl]acetophenone derivatives.EBI
TBA
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI
Pfizer
Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists.EBI
Zhejiang University
Modulators of leukotriene biosynthesis and receptor activation.EBI
Abbott Laboratories
Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionicEBI
Merck Frosst Centre For Therapeutic Research
The Role of Receptor Binding in Drug DiscoveryEBI
TBA
 
Discovery of L-740,515, a potent thienopyridine cysLT1 receptor (LTD4 receptor) antagonistEBI
TBA
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.EBI
University of Naples "Federico Ii
A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.EBI
Merck Frosst Center For Therapeutic Research
Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class.EBI
Novartis Pharma
Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists.EBI
Vrije Universiteit
High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid.EBI
TBA
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.EBI
Roche Research Center
Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.EBI
Ici Pharmaceuticals Group
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonist.EBI
Merck Frosst Centre For Therapeutic Research
The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency.EBI
Rorer Central Research
Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships.EBI
Rorer Central Research
Novel benzothiophene-, benzofuran-, and naphthalenecarboxamidotetrazoles as potential antiallergy agents.EBI
Warner-Lambert